<PAGE> 1
- -------------------------
FORM 3
- ------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(f) of the Investment Company Act of 1940
(Print or Type Responses)
________________________________________________________________________________
1. Name and Address of Reporting Person*
Merck & Co. Inc.
- --------------------------------------------------------------------------------
(Last) (First) (Middle)
One Merck Drive
- --------------------------------------------------------------------------------
(Street)
Whitehouse Station, New Jersey 08889
- --------------------------------------------------------------------------------
(City) (State) (Zip)
________________________________________________________________________________
2. Date of Event Requiring Statement (Month/Day/Year)
7/30/99
________________________________________________________________________________
3. IRS or Social Security Number of Reporting Person (Voluntary)
22-1109110
________________________________________________________________________________
4. Issuer Name and Ticker or Trading Symbol
SIBIA Neurosciences, Inc. (Symbol NASDAQ: SIBI)
________________________________________________________________________________
5. Relationship of Reporting Person to Issuer
(Check all applicable)
[_] Director [_] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
(See attached)
________________________________________________________________________________
6. If Amendment, Date of Original (Month/Day/Year)
________________________________________________________________________________
================================================================================
Table I -- Non-Derivative Securities Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------------------------
3. Ownership Form:
2. Amount of Securities Direct (D) or
1. Title of Security Beneficially Owned Indirect (I) 4. Nature of Indirect Beneficial Ownership
(Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5)
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Common Stock, par value
$0.001 per share 5,308,897 (see attached) (I) (see attached)
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
5(b)(v).
SEC 1473 (8-99)
Page 1 of 3
<PAGE> 2
<TABLE>
<CAPTION>
5. Owner-
3. Title and Amount of Securities ship
Underlying Derivative Security Form of
2. Date Exercisable (Instr. 4) Derivative
and Expiration Date --------------------------------- 4. Conver- Security:
(Month/Day/Year) Amount sion or Direct 6. Nature of
---------------------- or Exercise (D) or Indirect
Date Expira- Number Price of Indirect Beneficial
1. Title of Derivative Exer- tion of Derivative (I) Ownership
Security (Instr. 4) cisable Date Title Shares Security (Instr. 5) (Instr. 5)
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
Explanation of Responses:
This Initial Statement of Beneficial Ownership on Form 3 (this "Form 3")
is being filed by Merck & Co., Inc. a New Jersey corporation ("Merck") and MC
Subsidiary Corp. ("Merger Sub") a direct wholly owned subsidiary of Merck. On
July 30, 1999, Merck, Merger Sub and SIBIA Neurosciences, Inc. a Delaware
corporation ("SIBIA") entered into an Agreement and Plan of Merger (the "Merger
Agreement") providing for, among other things, the merger of SIBIA with and into
Merger Sub. Simultaneously with the execution and delivery of the Merger
Agreement, Merger Sub entered into a Shareholders Agreement dated July 30, 1999
(the "Shareholders Agreement") with certain shareholders of SIBIA (the "Lock-up
Shareholders") as follows: (i) The Salk Institute for Biological Studies -
1,933,461 shares; (ii) Skandigen AB - 986,696 shares; and (iii) William T. Comer
- - 267,900 shares and 189,790 options exercisable within 60 days. Under the
Shareholders Agreement, the Lock-up Shareholders have agreed, subject to the
terms thereof, to tender all of their shares of SIBIA Common Stock to Merger Sub
pursuant to the tender offer described in the Merger Agreement, and to vote
their shares in favor of the merger described in the Merger Agreement. The
Lock-up Shareholders have also granted Merger Sub a proxy to vote their shares,
representing approximately 34.1% of the issued and outstanding shares of SIBIA
Common Stock as of July 23, 1999, in favor of the merger. Simultaneously with
the execution and delivery of the Merger Agreement, Merck also entered into an
Option Agreement (the "Company Option") pursuant to which SIBIA granted to Merck
an option to purchase 1,931,050 shares of Common Stock, subject to the terms
thereof. If this option were to be exercised and these shares were issued to
Merck and outstanding, such shares would, together with the shares subject to
the Shareholders Agreement, represent approximately 44.9% of the issued and
outstanding shares of SIBIA Common Stock as of July 23, 1999.
The foregoing summary of the Shareholders Agreement and Company Option is
qualified in its entirety by reference to such agreements, which have been filed
as exhibits to the Schedule 13D and the Schedule 14D-1 filed with respect to
SIBIA on the date hereof.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
/s/ Judy C. Lewent 8/6/99
------------------------------- -------
**Signature of Reporting Person Date
Senior Vice President and Chief
Financial Officer
on behalf of MERCK & CO., INC.
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, See Instruction 6 for procedure.
SEC 1473 (8-99)
Page 2 of 3
<PAGE> 3
Joint Filer Information
Name: MC Subsidiary Corp.
Address: c/o Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey 08889
Designated Filer: Merck & Co., Inc.
Issuer & Ticker Symbol: SIBIA Neurosciences, Inc. (SIBI)
Date of Event Requiring Statement: 7/30/99
Signature: MC SUBSIDIARY CORP.
By: /s/ Judy C. Lewent
-------------------------------
Name: Judy C. Lewent
Title: President
SEC 1473 (8-99)
Page 3 of 3
